IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase I, first-in-human, randomised, double-blinded, placebo-and active-controlled
study to assess the safety, tolerability, PK, PD, efficacy, and food-effect of IDG-16177 in
healthy male subjects and patients with T2DM at different dose levels.